Impact of extended interval dosing of ocrelizumab on immunoglobulin levels in multiple sclerosis
Aaron Schuckmann, Falk Steffen, Frauke Zipp, Stefan Bittner, Katrin Pape
Topics & Concepts
OcrelizumabMedicineMultiple sclerosisDosingHypogammaglobulinemiaExpanded Disability Status ScaleInternal medicineRegimenAntibodyImmunologyRituximabMultiple Sclerosis Research StudiesPeripheral Neuropathies and DisordersRheumatoid Arthritis Research and Therapies